US/UK/Canada

Share

Links

Pick a time period -
Tags ( Active)

BerGenBio to present NSCLC and AML clinical data from Phase II development programme with selective AXL inhibitor bemcentinib at ASCO 2019

· Phase II data in AML combining bemcentinib with low-dose chemotherapy and NSCLC combining with KEYTRUDA · Accepted for presentation at ASCO in June 2019Bergen, Norway, 23 April 2019 – BerGenBio ASA (OSE: BGBIO) a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, announces that the Company and its collaborators will present new interim clinical and biomarker data from its extensive Phase II clinical development programme with bemcentinib, a selective, oral AXL inhibitor, at the 2019 annual meeting of the American

BerGenBio extends Phase II trial with bemcentinib and KEYTRUDA® in NSCLC to include patients with disease progression on immune checkpoint inhibitor therapy

· First patient dosed in new cohort of Phase II trial evaluating selective AXL inhibitor bemcentinib in combination with KEYTRUDA in patients with advanced NSCLC whose disease is progressing on anti-PD(L)1 therapy · New cohort added under existing collaborative agreement with Merck assessing the combination in previously treated advanced NSCLC · Decision to extend driven by encouraging preclinical data and high unmet need for treatment options after anti-PD(L)1 failureBergen, Norway, 2 April 2019 – BerGenBio ASA (OSE: BGBIO) announces that the first patient has been dosed in an

BerGenBio reports ~80% improvement in PFS of AXL-positive vs AXL-negative NSCLC patients in bemcentinib + KEYTRUDA PhII combination trial

· Late breaking abstract at SITC: Analysis of first stage of phase II trial with selective AXL inhibitor bemcentinib + KEYTRUDA in previously treated advanced NSCLC patients · Median progression-free-survival (mPFS) of 5.9 months in AXL positive vs 3.3 months in AXL negative patients (~80% improvement) · Predominantly PD-L1 negative or weak-positive patient populationBergen, Norway, 6 November 2018 - BerGenBio ASA (OSE:BGBIO) announces that a Late-breaking Abstract detailing median progression-free-survival (mPFS) during the first stage of its phase II clinical trial with bemcentinib,

BerGenBio to present late-breaking abstract on Phase II trial of bemcentinib in combination with KEYTRUDA® in advanced NSCLC at SITC

· Combination of selective AXL inhibitor bemcentinib and KEYTRUDA® featured in late breaking abstract at leading IO conference SITC · Analysis comprises stage 1 (n=24) in PhII trial in 2L advanced NSCLC · Stage 2 open and enrollingBergen, Norway, 2 November 2018 - BerGenBio ASA (OSE:BGBIO) announces that the analysis of the first stage of its Phase II clinical trial with bemcentinib, a first-in-class selective oral AXL inhibitor, in combination with the anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with previously treated, advanced non-small cell lung cancer (NSCLC) has been

BerGenBio announces interim biomarker and phase II clinical data with selective AXL inhibitor bemcentinib presented at ESMO

Biomarker predicts clinical benefit rate of 70% and overall response rate of 40% in second line NSCLC. Melanoma combination study reports safety and efficacy.Bergen, Norway, 22 October 2018 - BerGenBio ASA (OSE:BGBIO) announces that the company and its collaborators have presented interim clinical and biomarker data from BerGenBio’s Phase II clinical programme with bemcentinib (BGB324), a first-in-class highly selective oral AXL inhibitor, at the ESMO 2018 Congress in Munich (19 - 23 October 2018). Additionally, a pre-clinical study in myelodysplastic syndrome (MDS) was presented. The

BerGenBio enters second stage of phase II trial with selective AXL inhibitor bemcentinib in combination with KEYTRUDA® in patients with advanced NSCLC

Bergen, Norway, 5 October 2018– BerGenBio ASA (OSE: BGBIO) announces that the first patient has been dosed in the second stage of the phase II trial (BGBC008) evaluating the Company’s selective AXL inhibitor bemcentinib in combination with MSD’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with previously treated advanced adenocarcinoma of the lung (non-small cell lung cancer, NSCLC) whose disease is progressing.The trial was advanced into the second stage on the basis that the first stage met its clinical efficacy endpoint (as announced on 26 June 2018). Updated results from

BerGenBio: Updated phII clinical data with selective AXL inhibitor bemcentinib strengthens its potential to improve NSCLC patient outcomes

· Overall response rate of 40% with the bemcentinib/KEYTRUDA combination observed in AXL-positive, previously treated NSCLC patients, including PD-L1 negative patients who are not expected to benefit from KEYTRUDA monotherapy · Median PFS of patients receiving the bemcentinib/TARCEVA combination in first line has surpassed that of TARCEVA monotherapy · Encouraging efficacy reported for bemcentinib in combination with docetaxel chemotherapy in patients who had exhausted all available therapy options including anti-PD-(L)1 · Phase II trial design revealed combining bemcentinib and

Selective AXL inhibitor bemcentinib meets pre-specified efficacy endpoint in stage 1 of NSCLC phase II combination trial with KEYTRUDA®

· Clinical response merits initiation of stage 2 of the Phase II combination trial · 24 patients treated to date, 48 patients to be treated in total · Responses will be correlated with AXL and PD-L1 biomarkersBergen, Norway, June 26, 2018 – BerGenBio ASA (OSE:BGBIO) announces today that on a top-line, preliminary basis, the first efficacy endpoint has been met in its Phase II clinical trial (BGBC008) evaluating bemcentinib, a first-in-class oral selective AXL inhibitor, in combination with the Merck & Co., Inc., Kenilworth, N.J., USA[1] 

BerGenBio ASA: Results for the First Quarter 2018

Bergen, Norway, 15 May 2018 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, announces its results for the first quarter 2018. A presentation of the results by the Company’s management will take place today at 10.00 am CET in Oslo – details below.Richard Godfrey, Chief Executive Officer of BerGenBio, commented: “We are pleased with the progress made during Q1 2018. Patient recruitment into our global Phase II clinical proof-of-concept trials with bemcentinib is progressing well and we

BerGenBio participation at upcoming healthcare investor and life sciences industry conferences

Bergen, Norway, 14 May 2018– BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, will be participating at the following upcoming conferences.· 14-16 May, Bio€quity Europe 2018 (Ghent, Belgium)* · 23 May, ABG Sundal Collier Cancer Seminar (Stockholm, Sweden)* · 1 June, Sachs Immuno-Oncology BD&L and Investment Forum (Chicago, IL)* · 4 June, Norne Securities Conference (Bergen, Norway)*  · 1-5 June, 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO) (Chicago,

BerGenBio: Promising data highlighting selective AXL inhibitor bemcentinib’s potential to improve efficacy of checkpoint inhibitors presented at AACR

Bergen, Norway, 18 April 2018 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, announces that promising preclinical data with its lead AXL inhibitor bemcentinib (formerly BGB324) has been presented in a poster at the 2018 American Association for Cancer Research (AACR) Annual Meeting on 14-18 April in Chicago, IL, USA.The data highlight bemcentinib’s potential to reverse tumour immune suppression and enhance immune checkpoint inhibitor efficacy. The authors show that bemcentinib

BerGenBio completes recruitment into first stage of Phase II NSCLC trial with selective AXL inhibitor bemcentinib combined with KEYTRUDA®

Bergen, Norway, 10 April 2018 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors as a potential cornerstone of combination cancer therapy in NSCLC, AML/MDS, TNBC and melanoma, announces that it has completed enrolment of the planned 22 patients into the first stage of its Phase II clinical trial evaluating bemcentinib (formerly BGB324), its investigational oral selective AXL inhibitor, in combination with the Merck & Co., Inc., Kenilworth, N.J., USA (known as MSD outside the United States and Canada) anti-PD-1 therapy

BerGenBio to present overview of phase II clinical trial portfolio combining bemcentinib with KEYTRUDA at 3rd Annual Immuno-Oncology Summit Europe

Bergen, Norway, 22 March 2018 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors as a potential cornerstone of combination cancer therapy, announces that the Company will be presenting an overview of the three ongoing phase II trials combining the Company’s selective AXL inhibitor bemcentinib with the anti-PD-1 therapy KEYTRUDA at the 3rd Annual Immuno-Oncology Summit Europe, London, UK, today at 10:05-10:35 GMT.The presentation will be delivered by Dr. Julia Schoelermann, Assoc. Director Business Development &

BerGenBio completes recruitment into first stage of Phase II breast cancer trial with selective AXL inhibitor bemcentinib combined with KEYTRUDA®

Bergen, Norway, 19 February 2018 – BerGenBio ASA  (OSE: BGBIO) announces that it has completed enrolment, ahead of schedule, of the planned 28 patients into the first stage of its Phase II clinical trial evaluating its investigational oral selective AXL inhibitor bemcentinib (BGB324) in combination with the Merck & Co., Inc., Kenilworth, N.J., USA (known as MSD outside the United States and Canada) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) as a potential new treatment regimen for advanced breast cancer.The Phase II trial (BGBC007) follows a two-stage design: it

BerGenBio ASA: Results for the Fourth Quarter and Full Year 2017

Bergen, Norway, 13 February 2018 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, announces its results for the fourth quarter and full year 2017. A presentation of the results by the Company’s senior management team will take place today at 10.00 am CET in Oslo – details below.Richard Godfrey, Chief Executive Officer of BerGenBio, commented: “BerGenBio has made solid progress during 2017 and achieved all of the milestones we outlined at the time of our IPO in April. We have advanced,

BerGenBio: Encouraging I-O clinical data with selective AXL inhibitor bemcentinib (BGB324) supports its potential as cornerstone of cancer therapy

· Favourable interim safety data reported across three phase II clinical trials with bemcentinib in combination with KEYTRUDA® (pembrolizumab) · Immune response demonstrated in AML patients treated with bemcentinib monotherapy in phase II clinical trial · Two posters featuring four of BerGenBio’s six phase II clinical trials with selective AXL inhibitor bemcentinib presented at the ASCO-SITC Clinical Immuno-Oncology SymposiumBergen, Norway, January 29, 2018 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company focused on developing bemcentinib as a potential

BerGenBio ASA: Results for the Third Quarter 2017

Bergen, Norway, 17 November 2017 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors for multiple cancer indications, announces its results for the third quarter 2017. A presentation of the results by the Company’s senior management team will take place today at 9.00 am CET in Oslo – details below.Richard Godfrey, Chief Executive Officer of BerGenBio, commented: “We are very pleased with the progress the company has made during Q3 2017. Our broad clinical development programme of Phase 2 trials with BGB324, our

BerGenBio Presents BGB324 and KEYTRUDA® (pembrolizumab) Clinical Trial at the 2017 San Antonio Breast Cancer Symposium

Bergen, Norway, 14 Nov 2017 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors for multiple cancer indications, is pleased to announce that the Company will present its recently initiated Phase II clinical trial investigating BGB324 in combination with the Merck & Co., Inc., Kenilworth, N.J., USA (known as MSD outside the United States and Canada) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with triple negative breast cancer (TNBC) at the 2017 San Antonio Breast Cancer Symposium in San Antonio, USA (5-9 Dec

BerGenBio Announces Start of Ph II Trial Assessing Selective AXL Inhibitor BGB324 in Combination with KEYTRUDA® for Patients with Advanced Lung Cancer

Bergen, Norway, 24 Oct 2017 – BerGenBio ASA (OSE: BGBIO) , a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class Axl kinase inhibitors to treat multiple cancer indications, announces that the first patient has been dosed in a Phase II trial evaluating the Company’s lead product BGB324 in combination with KEYTRUDA® (pembrolizumab) in patients with previously treated advanced adenocarcinoma of the lung (non-small cell lung cancer, NSCLC) whose disease is progressing. The trial is being sponsored by BerGenBio. MSD (tradename of

BerGenBio Announces Start of PhII Trial Assessing Selective AXL Inhibitor BGB324 in Combination with KEYTRUDA for Patients with Advanced Breast Cancer

Bergen, Norway, 19 October 2017 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class Axl kinase inhibitors to treat multiple cancer indications, announces that the first patient has been dosed in a Phase II trial evaluating the Company’s lead product BGB324 in combination with KEYTRUDA® (pembrolizumab) in patients with previously treated, locally advanced and unresectable or metastatic triple-negative breast cancer (TNBC) or triple negative inflammatory breast cancer (TN-IBC). The trial is being sponsored by BerGenBio. MSD

BGB324, BerGenBio's Selective First-in-Class AXL Inhibitor, Featured in 3 Clinical Presentations at 18th World Conference on Lung Cancer in Yokohama

Bergen, Norway, October 16, 2017 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors for multiple cancer indications, announces presentations on three ongoing Phase 2 clinical trials with BGB324 in lung cancer patients at the 18th World Conference on Lung Cancer in Yokohama, Japan.BGB324, a first-in-class selective Axl inhibitor, is being investigated in three Phase 2 clinical trials across the three standard-of-care treatment regimens available to patients with non-small-cell lung cancer (NSCLC): these trials seek to

Clinical Study with BGB324, BerGenBio’s Selective First-in-Class AXL Inhibitor, to be Presented at the 9th World Congress of Melanoma

Bergen, Norway, Oct 12 2017 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors for multiple cancer indications, announces that the clinical trial of BGB324 in combination with either MEKINIST® (trametinib) plus TAFINLAR® (dabrafenib) or KEYTRUDA® in advanced melanoma, will be presented at the 9th World Congress of Melanoma in Brisbane, Australia, October 18-21, 2017.Dr. Oddbjørn Straume, consultant oncologist at Haukeland University Hospital and Professor at the University of Bergen Centre for Cancer Biomarkers will

BGB324, BerGenBio's Selective First-in-Class AXL Inhibitor, Featured in Three Clinical Presentations at the 18th World Conference on Lung Cancer

Bergen, Norway, Sep 28 2017 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors  for multiple cancer indications, is pleased to announce that the Company will present three ongoing lung cancer clinical trials with BGB324 at the 18th World Conference on Lung Cancer in Yokohama, Japan, October 15 – 18, 2017.The three presentations will show clinical results to date and discuss the rationale of the clinical studies undertaken with BGB324, BerGenBio’s lead candidate, a first-in-class and highly

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Media